Insider buying last 90 days
No open-market insider purchases were filed for HQY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
HealthEquity reached a 52-week high of $107.75 this week, extending a run built on strong HSA growth, AI-driven efficiencies and a raised fiscal 2027 outlook, with cybersecurity risks flagged as an ongoing concern. The company also confirmed it will release third-quarter fiscal 2027 results after the close on 1 December 2026, with an investor call to follow. Separately, HQY has been compared against Bausch + Lomb (BLCO) on relative value grounds.
Shares closed at $102.11, down 1.5% on the day, but remain above both the 50-day ($95.64) and 200-day ($89.57) moving averages, with the shorter average above the longer one, pointing to a supportive trend. The GekkoIndex reads 52.3, placing HQY in the Neutral zone. Fair value work puts Gekko Fair Value at $173.68, leaving the stock 41.2% below that level.
The next 20 trading days bring the fiscal third-quarter report on 1 December 2026, falling inside that window and carrying average absolute reactions of 6.5% historically, with 7 beats in the last 8 quarters. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows, though one billionaire holder and one trailblazer holder are noted. Seasonality over this stretch has averaged -9.6% across 5 years, rising in 2 of them, a contrast worth noting against the current uptrend and analyst consensus target of $120.67 from 9 firms, all rated buy.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
HealthEquity scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $103.46 is above the 50-day ($96.08) and 200-day ($89.96) averages, and the 50-day is above the 200-day.
See the chart53, Neutral
Reading 53 is in the Neutral zone.
See the GekkoIndex42.6% below
Price is 42.6% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 16 days
Reports on Dec 1, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings−10.3% on average
From this point in the calendar, the next 20 trading days averaged −10.3% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
HealthEquity closed at $103.46 on Nov 13, 2026, +2.9% over the past year, inside a 52-week range of $72.76 to $110.26.
Use the left and right arrow keys to read daily values.
Put HQY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
HealthEquity offers digital tools that let everyday people and the businesses that employ them keep tabs on healthcare costs and savings. Users can settle medical bills, weigh treatment choices against their prices, view tailored benefit details and clinical records, collect rewards for healthy habits, and build savings using a range of investment options. The company has become closely tied to Health Savings Accounts, which it manages alongside Flexible Spending Accounts and Health Reimbursement Arrangements for its customers nationwide.
On top of these account services, HealthEquity runs a mutual fund investment platform, a digital advisory tool called Advisor, continuation coverage support under COBRA rules, and administration of commuter benefit programs funded with pre-tax dollars. To reach its market, the company relies on its own sales staff as well as ties with benefits brokers and advisors, and it works alongside health plans, benefits administrators, consultants, and record-keepers for retirement plans.
The company traces its founding to 2002 and keeps its headquarters in Draper, Utah. HealthEquity trades on the NASDAQ under the ticker HQY.
HealthEquity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53, in the Neutral zone, up 3.5 points over five sessions.
Up 3.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 17 | +3.0% | +5.6% | ||
| Accumulation | 224 | +0.1% | +0.6% | ||
| Neutral (current zone) | 411 | +0.5% | +1.8% | ||
| Distribution | 47 | −0.5% | −3.7% | ||
| Selling | 3 | Too few readings yet | |||
Average HQY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
HealthEquity trades 42.6% below Gekko Fair Value of $180.37, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what HealthEquity shares are worth, recalculated every trading day.
$180.37
Gekko Fair Value, Nov 14, 2026
42.6% Undervalued
At the end of Aug 2026 the price was 13.3% below the estimate.
No open-market insider purchases were filed for HealthEquity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HQY in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HQY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
HealthEquity has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold HQY.
HealthEquity reports on Dec 1, 2026, after the close (16 days away), and beat the EPS estimate in 7 of its last 8 reports.
Dec 1, 2026
Expected after the close, 16 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 27, 2026 | $1.24 est $1.19 | $350.7M est $349.2M | −7.7% |
| May 28, 2026 | $1.07 est $0.94 | $354.6M est $352.0M | +1.7% |
| Mar 17, 2026 | $0.95 est $0.90 | $334.6M est $332.3M | +1.1% |
| Dec 3, 2025 | $1.01 est $0.91 | $322.2M est $320.6M | −3.2% |
| Sep 2, 2025 | $1.08 est $0.91 | $325.8M est $320.7M | +7.0% |
| Jun 3, 2025 | $0.97 est $0.81 | $330.8M est $322.3M | +10.0% |
| Mar 18, 2025 | $0.69 est $0.72 | $311.8M est $305.8M | −16.3% |
| Dec 9, 2024 | $0.78 est $0.72 | $300.4M est $290.1M | −4.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for HealthEquity is $120.67, +16.6% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 21 | BMO Capital | $125 | +20.8% |
| Oct 16 | Bank of America Securities | $125 | +20.8% |
| Oct 6 | RBC Capital | $108 | +4.4% |
| Sep 29 | Wells Fargo | $125 | +20.8% |
| Sep 25 | Wells Fargo | $125 | +20.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, HealthEquity averaged −10.3% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 2 of 5 |
| Next 10 trading days | −2.9% | 2 of 5 |
| Next 15 trading days | −6.9% | 3 of 5 |
| Next 20 trading days | −10.3% | 1 of 5 |
| Next 30 trading days | −9.6% | 1 of 5 |
For scale, HQY’s typical 20-trading-day move in either direction is about 7.4%.
HealthEquity’s market cap is $8.56B, with a P/E ratio of 37.4 and revenue of $1.36B over the last twelve months.
1 headline about HealthEquity from the past week, newest first, each linking to the publisher.
HealthEquity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSMorgan Stanley | Neutral | 4.8% below |
| BLKBlackRock | Neutral | 0.9% above |
| UBSUBS | Neutral | 6.2% below |
| BXBlackstone | Neutral | 5.3% below |
| BNBrookfield | Neutral | 8.7% below |
| KKRKKR | Neutral | 7.1% below |
A peer links to its own page where one exists.
HealthEquity’s market cap is $8.56B at the Nov 13, 2026 close of $103.46, with 82.72M shares outstanding. The shares trade on a P/E ratio of 37.4.
The consensus analyst 12-month price target for HealthEquity is $120.67, +16.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate HealthEquity is undervalued: the Nov 13, 2026 close of $103.46 is 42.6% below Gekko Fair Value of $180.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
HealthEquity is expected to report on Dec 1, 2026, after the market closes (16 days away). Analysts expect earnings of $1.15 per share on revenue of $347.2M. HealthEquity beat the earnings estimate in 7 of its last 8 reports, moving 6.5% on average across the report.
HealthEquity’s 52-week high is $110.26 and its 52-week low is $72.76; it closed at $103.46 on Nov 13, 2026, +2.9% over the past year. Over the last five years the shares peaked at $116.65 on Jun 5, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.